Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 109

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 109
---
 collaboration involving any of our drug and diagnostics technology candidates, the arrangement will be subject to numerous risks, which may include the following: •the collaborators will likely have significant discretion in determining the efforts and resources that they will apply to a collaboration; •the collaborator may ultimately choose not pursue development and commercialization of our drug or diagnostics technology candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities; •the collaborator may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug or diagnostics technology candidate, repeat or conduct new clinical trials, or require a new formulation of a drug or diagnostics technology candidate for clinical testing; •the collaborator could independently develop, or develop with unrelated parties, drugs that compete directly or indirectly with our drugs or drug candidates; 44 •the collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to their marketing and distribution; •the collaborator may not properly maintain or defend our IP rights or may use our IP or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our IP or proprietary information or expose us to potential liability; •disputes may arise between us and the collaborator that cause the delay or termination of the research, development or commercialization of our drug and diagnostics technology candidates, or that result in costly litigation or arbitration that diverts management attention and resources; •the collaboration may be terminated and, if terminated, may result the Company needing additional capital to pursue further development or commercialization of the applicable drug and diagnostics technology candidates; •the collaborator may own or co -ownIP covering our drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such IP; •the collaboration may result in increased operating expenses or the assumption of indebtedness or contingent liabilities; and •the collaboration arrangement may result in the loss of key personnel and uncertainties in our ability to maintain key business relationships. As a result, if we enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions, which could delay our timelines or otherwise adversely affect our business. Following a strategic transaction or license, we may not achieve the revenue or specific net income that justifies such